Mikhail Kesler1, Kosta Kerzhner1, Ido Druckmann2, Jonathan Kuten1, Charles Levine1, David Sarid3, Daniel Keizman3, Ofer Yossepowitch4,5, Einat Even-Sapir6,7. 1. Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 6423906, Tel Aviv, Israel. 2. Department of Radiology-Musculoskeletal Imaging Unit, Imaging Division, Tel Aviv Sourasky Medical Center, 6423906, Tel Aviv, Israel. 3. Department of Oncology (Uro-Oncology Section), Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, 6423906, Tel Aviv, Israel. 4. Department of Urology, Tel Aviv Sourasky Medical Center, 6423906, Tel Aviv, Israel. 5. Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. 6. Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 6423906, Tel Aviv, Israel. evensap@tlvmc.gov.il. 7. Sackler School of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. evensap@tlvmc.gov.il.
Abstract
PURPOSE: The aim of the study was to elaborate the incidence and type of skeletal involvement in a large cohort of patients with newly diagnosed prostate cancer (PCa) referred for Ga-68 PSMA-11 PET/CT staging in a single center. METHODS: Study cohort included 963 consecutive patients with newly diagnosed PCa referred for Ga-68 PSMA-11 PET/CT study for staging. The incidence of bone involvement, type of bone metastases, and extent of disease were determined and correlated with the ISUP Grade Group (GG) criteria and PSA levels. RESULTS: Bone metastases were found in 188 (19.5%) of 963 patients. Bone metastases were found in 10.7% of patients with PSA < 10 ng/dL and in 27.4% of patients with PSA > 10 ng/dL and in 6.1% of patients with GG ≤ 2/3 and in 8.9% of patients with GG 4/5. In 7.6% of the patients, skeletal involvement was extensive, while 11.9% of patients had oligometastatic disease. Osteoblastic type metastases were the most common type of bone metastases presented in 133 of the patients with malignant bone involvement (70.7%). More than half of them had only osteoblastic lesions (72 patients (38.3%)), while the other (61 patients (32.5%)) had also intramedullary and/or osteolytic type lesions. Intramedullary metastases were found in 97 patients (51.6%), while 41 (21.8%) of them were only intramedullary lesions. Osteolytic metastases were detected in 36 patients (19.2%), of which 8 were only osteolytic lesions. CONCLUSION: Although traditionally bone metastases of PCa are considered osteoblastic, osteolytic and intramedullary metastases are common, as identified on PET with labeled PSMA. Skeletal spread may be present also in patients with GG ≤ 2/3 and PSA < 10 ng/dL.
PURPOSE: The aim of the study was to elaborate the incidence and type of skeletal involvement in a large cohort of patients with newly diagnosed prostate cancer (PCa) referred for Ga-68 PSMA-11 PET/CT staging in a single center. METHODS: Study cohort included 963 consecutive patients with newly diagnosed PCa referred for Ga-68 PSMA-11 PET/CT study for staging. The incidence of bone involvement, type of bone metastases, and extent of disease were determined and correlated with the ISUP Grade Group (GG) criteria and PSA levels. RESULTS: Bone metastases were found in 188 (19.5%) of 963 patients. Bone metastases were found in 10.7% of patients with PSA < 10 ng/dL and in 27.4% of patients with PSA > 10 ng/dL and in 6.1% of patients with GG ≤ 2/3 and in 8.9% of patients with GG 4/5. In 7.6% of the patients, skeletal involvement was extensive, while 11.9% of patients had oligometastatic disease. Osteoblastic type metastases were the most common type of bone metastases presented in 133 of the patients with malignant bone involvement (70.7%). More than half of them had only osteoblastic lesions (72 patients (38.3%)), while the other (61 patients (32.5%)) had also intramedullary and/or osteolytic type lesions. Intramedullary metastases were found in 97 patients (51.6%), while 41 (21.8%) of them were only intramedullary lesions. Osteolytic metastases were detected in 36 patients (19.2%), of which 8 were only osteolytic lesions. CONCLUSION: Although traditionally bone metastases of PCa are considered osteoblastic, osteolytic and intramedullary metastases are common, as identified on PET with labeled PSMA. Skeletal spread may be present also in patients with GG ≤ 2/3 and PSA < 10 ng/dL.
Authors: Kevin J Donohoe; Erica J Cohen; Francesco Giammarile; Erin Grady; Bennett S Greenspan; Robert E Henkin; John Millstine; Gary T Smith; Sandy Srinivas; Julie Kauffman; Sukhjeet Ahuja Journal: J Nucl Med Date: 2017-04 Impact factor: 10.057
Authors: Mette Nørgaard; Annette Østergaard Jensen; Jacob Bonde Jacobsen; Kara Cetin; Jon P Fryzek; Henrik Toft Sørensen Journal: J Urol Date: 2010-05-16 Impact factor: 7.450
Authors: Christos Sachpekidis; P Bäumer; K Kopka; B A Hadaschik; M Hohenfellner; A Kopp-Schneider; U Haberkorn; A Dimitrakopoulou-Strauss Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-23 Impact factor: 9.236
Authors: Fergus V Coakley; Aytekin Oto; Lauren F Alexander; Brian C Allen; Brian J Davis; Adam T Froemming; Pat F Fulgham; Keyanoosh Hosseinzadeh; Christopher Porter; V Anik Sahni; David M Schuster; Timothy N Showalter; Aradhana M Venkatesan; Sadhna Verma; Carolyn L Wang; Erick M Remer; Steven C Eberhardt Journal: J Am Coll Radiol Date: 2017-05 Impact factor: 5.532
Authors: Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger Journal: Eur J Nucl Med Mol Imaging Date: 2008-05-09 Impact factor: 9.236
Authors: Martin G Sanda; Jeffrey A Cadeddu; Erin Kirkby; Ronald C Chen; Tony Crispino; Joann Fontanarosa; Stephen J Freedland; Kirsten Greene; Laurence H Klotz; Danil V Makarov; Joel B Nelson; George Rodrigues; Howard M Sandler; Mary Ellen Taplin; Jonathan R Treadwell Journal: J Urol Date: 2017-12-15 Impact factor: 7.450
Authors: Maarten L Donswijk; Pim J van Leeuwen; Erik Vegt; Zing Cheung; Stijn W T P J Heijmink; Henk G van der Poel; Marcel P M Stokkel Journal: BMC Cancer Date: 2020-08-05 Impact factor: 4.430